local_hospital

Klinische Forschung Karlsruhe GmbH

Address
lock Available on a paid plan

Cardiovascular and Metabolic Research

At Klinische Forschung Karlsruhe GmbH, clinical trials in cardiovascular diseases and nutritional and metabolic diseases focus on conditions such as atherosclerotic cardiovascular disease, hyperlipidemia, elevated Lp(a), uncontrolled hypertension, and obesity. These studies are designed to test new treatments and assess whether they can reduce risk and improve long-term heart and metabolic health.

  • Testing therapies aimed at lowering cardiovascular risk, including major heart and vascular events
  • Evaluating treatments for high cholesterol, elevated lipoprotein(a), and resistant hypertension
  • Studying weight management approaches for people with obesity and related cardiometabolic conditions

The site’s work in this area brings together prevention-focused research and treatment studies for common risk factors that contribute to serious cardiovascular disease.

Pain, Musculoskeletal, and Neurological Studies

Research at this site also covers musculoskeletal diseases and nervous system diseases, with trials in osteoarthritis, chronic low back pain, diabetic peripheral neuropathic pain, and related pain conditions. The main goal is to evaluate new ways to relieve persistent pain and improve daily function for people living with long-term joint or nerve-related problems.

  • Assessing pain relief options for knee osteoarthritis and chronic non-specific low back pain
  • Investigating treatments for diabetic nerve pain and other difficult-to-manage pain syndromes
  • Exploring therapies that may improve comfort, mobility, and quality of life

This is a strong area of clinical research at Klinische Forschung Karlsruhe GmbH, especially for conditions where standard pain treatment has not been enough.

Digestive, Immune, and Hematology Research

The portfolio includes digestive system diseases, immune system diseases, and hemic and lymphatic diseases, with studies in irritable bowel syndrome, gout with hyperuricemia, and chronic lymphocytic leukemia/small lymphocytic lymphoma. These trials aim to improve symptom control, support disease management, and evaluate whether new or alternative treatments work better than current options.

  • Testing therapies for IBS, including diarrhea-predominant and mixed forms
  • Evaluating treatments for gout and elevated uric acid levels
  • Studying new approaches for blood cancer care in CLL/SLL

This research reflects a broad interest in both chronic gastrointestinal symptoms and more specialized immune and blood-related conditions.

Respiratory, Infectious, and Vaccine Research

Trials in respiratory tract diseases and virus diseases include work on influenza, refractory chronic cough, and chronic obstructive pulmonary disease. The research is centered on improving prevention and symptom control, while also examining the safety and effectiveness of vaccine and treatment options for common respiratory illnesses.

  • Evaluating influenza vaccine performance and immune response in older adults
  • Studying new treatments for persistent or unexplained chronic cough
  • Exploring therapies for chronic lung disease and related respiratory symptoms

These studies highlight the site’s role in both infectious disease prevention and the management of ongoing respiratory conditions.

Psychiatry, Sleep, Skin, and Women’s Health Research

Additional trials address mental disorders, skin and connective tissue diseases, and female urogenital diseases and pregnancy complications. Key topics include major depressive disorder, insomnia disorder, female androgenetic alopecia, and primary dysmenorrhea, with the aim of improving symptom relief and everyday well-being through better treatment options.

  • Testing treatments for depression and sleep problems
  • Evaluating hair loss therapies in women with hormone-related hair thinning
  • Studying relief options for menstrual pain and related discomfort

Together, these studies show a diverse research profile that extends beyond internal medicine into mental health, dermatology, and women’s health.

Site Overview

assignment
24
connected trials
corporate_fare
18
sponsors
science
39
IMPs

Activity Indicator

Last 6 months

2
Trials started
-33% vs previous period.
3
Trials started 6–12 months ago
24
Total trials linked
Highly Active
trending_downDeclining-33%
2
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 13 therapeutic areas and 15 of 39 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
6
Sponsors (total)
18
Active sponsors
6

Sponsor Network

Top 6 by active trials.

lock +5 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +4 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
24
Outperforms 91% of sites
public
Therapeutic diversity
14areas
Outperforms 98% of sites
groups
Sponsor diversity
18sponsors
Outperforms 93% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Klinische Forschung Karlsruhe GmbH

lock Showing 1 of 24 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients with HyperuricemiaLG Chem Ltd.Phase IIINot RecruitingApr 2024Apr 2025

IMP list

lock Showing 1 of 39 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Paracetamol3Unknown2024-02-132024-02-13

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.